UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 166

Sortiert nach

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Annals of oncology, 2023-09, Vol.34 (9), p.772-782

2023

Volltextzugriff (PDF)

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Annals of oncology, 2022-09, Vol.33 (9), p.909-915

2022

Volltextzugriff (PDF)

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Annals of oncology, 2022-10, Vol.33 (10), p.1041-1051

2022

Volltextzugriff (PDF)

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study

European journal of cancer (1990), 2024-03, Vol.199, p.113534-113534, Article 113534

2024

Volltextzugriff (PDF)

French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2022-11, Vol.32 (15), p.1275-1372

2022

Volltextzugriff (PDF)

The role of radiation therapy for de novo metastatic bladder and renal cancers

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2024-02, Vol.28 (1), p.56-65

2024

Volltextzugriff (PDF)

French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2022-11, Vol.32 (15), p.1373-1419

2022

Volltextzugriff (PDF)

Early detection of prostate cancer: Towards a new paradigm?

Progrès en urologie (Paris), 2023-12, Vol.33 (15-16), p.956-965

2023

Volltextzugriff (PDF)

DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology

Progrès en urologie (Paris), 2022-03, Vol.32 (3), p.155-164

2022

Volltextzugriff (PDF)

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

European journal of cancer (1990), 2017-12, Vol.87, p.140-146

2017

Volltextzugriff (PDF)

Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology

Progrès en urologie (Paris), 2022-09, Vol.32 (10), p.623-634

2022

Volltextzugriff (PDF)

Plan of the day adaptive radiotherapy for bladder cancer: Dosimetric and clinical results

Cancer radiothérapie, 2021-06, Vol.25 (4), p.308-315

2021

Volltextzugriff (PDF)

How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?

Progrès en urologie (Paris), 2022-06, Vol.32 (6S1), p.6S43-6S53

2022

Volltextzugriff (PDF)

A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer

ESMO open, 2024-06, Vol.9 (6), p.103446, Article 103446

2024

Volltextzugriff (PDF)

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review

Prostate cancer and prostatic diseases, 2014-09, Vol.17 (3), p.220-226

2014

Volltextzugriff (PDF)

Enzalutamide and sleep apnea: an emerging central nervous system side-effect?

Annals of oncology, 2016-01, Vol.27 (1), p.206-206

2016

Volltextzugriff (PDF)

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

Annals of oncology, 2014-09, Vol.25 (9), p.1775-1782

2014

Volltextzugriff (PDF)

EP-1386: Adjuvant pelvic radiotherapy for pathological high-risk muscle-invasive bladder cancer

Radiotherapy and oncology, 2016-04, Vol.119, p.S647-S647

2016

Volltextzugriff (PDF)

Hypofractionnated radiotherapy for elderly patients with prostate cancer

Cancer radiothérapie, 2018-10, Vol.22 (6-7), p.631-634

2018

Volltextzugriff (PDF)

Oncological and functional results of robotic salvage radical prostatectomy after permanent brachytherapy implants

Cancer radiothérapie, 2017-04, Vol.21 (2), p.119-123

2017

Volltextzugriff (PDF)

Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

Annals of oncology, 2014-06, Vol.25 (6), p.1248-1249

2014

Volltextzugriff (PDF)

2594 Safety and efficacy of Temsirolimus (Torisel®) as second line treatment for patients with recurrent bladder cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S509-S509

2015

Volltextzugriff (PDF)

Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?

Cancer radiothérapie, 2017-02, Vol.21 (1), p.67-72

2017

Volltextzugriff (PDF)

Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series

Annals of oncology, 2012-03, Vol.23 (3), p.804-805

2012

Volltextzugriff (PDF)

Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma

Oncology, 2011-01, Vol.80 (3-4), p.214-218

2011

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(155)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study

French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease

The role of radiation therapy for de novo metastatic bladder and renal cancers

French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance

Early detection of prostate cancer: Towards a new paradigm?

DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology

Plan of the day adaptive radiotherapy for bladder cancer: Dosimetric and clinical results

How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?

A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review

Enzalutamide and sleep apnea: an emerging central nervous system side-effect?

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

EP-1386: Adjuvant pelvic radiotherapy for pathological high-risk muscle-invasive bladder cancer

Hypofractionnated radiotherapy for elderly patients with prostate cancer

Oncological and functional results of robotic salvage radical prostatectomy after permanent brachytherapy implants

Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

2594 Safety and efficacy of Temsirolimus (Torisel®) as second line treatment for patients with recurrent bladder cancer

Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?

Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series

Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma

Suchergebnisse filtern